The ongoing observational study sponsored by Research Center Borstel aims to identify novel biomarkers for the non-invasive diagnosis of tuberculosis, a significant global health concern. The market for TB diagnostics is expanding due to the increasing incidence of drug-resistant TB and the need for rapid, accurate diagnostic tools. The study's focus on non-invasive methods may position it favorably against existing diagnostic techniques that often require sputum samples, which can be challenging for certain patient populations. Competitive implications include potential partnerships with diagnostic companies and the opportunity to develop proprietary tests based on identified biomarkers. Diligence considerations should include the regulatory pathway for any resulting diagnostic products and the potential for intellectual property protection around the biomarkers identified.